Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?

Abstract : Ibrutinib is a novel oral covalent inhibitor of Bruton's tyrosine kinase (BTK). It has been approved for the treatment of relapsing chronic lymphocytic leukemia (CLL), or CLL with high-risk cytogenetic abnormalities. Several cases of invasive aspergillosis have recently been reported in ibrutinib-treated patients. We report two cases of cerebral aspergillosis in CLL patients treated with ibrutinib.
Complete list of metadatas

Cited literature [10 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01807746
Contributor : Laurent Jonchère <>
Submitted on : Thursday, June 21, 2018 - 4:25:55 PM
Last modification on : Tuesday, July 3, 2018 - 2:40:00 PM
Long-term archiving on : Tuesday, September 25, 2018 - 12:03:49 PM

File

Cerebral aspergillosis_accepte...
Files produced by the author(s)

Identifiers

Citation

E Gaye, Audrey Le Bot, Jean-Philippe Talarmin, Ronan Le Calloch, Sorya Belaz, et al.. Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?. Médecine et Maladies Infectieuses, Elsevier Masson, 2018, 48 (4), pp.294-297. ⟨10.1016/j.medmal.2018.01.003⟩. ⟨hal-01807746⟩

Share

Metrics

Record views

487

Files downloads

135